TD Asset Management
LRMR icon

TD Asset Management’s Larimar Therapeutics LRMR Stock Holding History

TD Asset Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,533
Closed -$269K – 1372
2018
Q4 		$269K Sell
4,533
-184
-4% -$18.2K ﹤0.01% 1318
2018
Q3 		$662K Buy
+4,717
New +$573K ﹤0.01% 1239

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TD Asset Management's LRMR Position: Q1 2019 in Review

TD Asset Management sold out of Larimar Therapeutics (LRMR) in Q1 2019, closing a stake of 4,533 shares — an estimated $269K sold.

TD Asset Management first reported a position in LRMR in Q3 2018 and held it in 2 quarters. The position peaked at $662K in Q3 2018. 85 funds tracked by Wall St. Rank hold LRMR as of Q1 2019.

  • TD Asset Management reported no remaining Larimar Therapeutics position as of Q1 2019 after selling out during the quarter.
  • TD Asset Management sold 4,533 Larimar Therapeutics shares in Q1 2019, an estimated $269K.
  • TD Asset Management first reported a position in Larimar Therapeutics in Q3 2018 and held it in 2 quarters.
  • TD Asset Management's Larimar Therapeutics position peaked at $662K in Q3 2018.
  • 85 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2019.

Based on TD Asset Management's 13F filing for Q1 2019, filed 8 May 2019.